News

Jonathan Meyer, MD, previews his session on updates in tardive dyskinesia at the upcoming 2025 Southern California Psychiatry Conference.

Pseudoexfoliation results in the ganglion cell layer degradation that precedes glaucoma, indicating a potential predictor.

This Q&A interview with Lisa Swanson, MD, features a discussion of the highlights of Swanson’s talk at RAD 2025 regarding pediatric atopic dermatitis.

An audio recap of the top 5 stories in healthcare news from the week of 06/02-06/08.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and new phase 3 clinical trial data, in this week's essential news roundup.

Explore the latest advancements in biologic therapies for asthma and COPD discussed in a recent clinical forum highlighting personalized medicine and biomarker-driven strategies for improved patient outcomes.

The recent Lancet Commission on Obesity has repositioned the former risk factor as a disease, indicating and emphasizing a variety of complications.

Successful HCV treatment with DAAs was associated with reduced risks of CKD, stroke, major adverse cardiac events, and neurocognitive disorders.

By targeting insulin resistance at its source, dual receptor agonists may have a more efficient method of tackling the growing obesity problem, as well as its cardiovascular effects.

Use of an AI-guided infection prevention bundle did not significantly reduce CDI incidence but was associated with increased antimicrobial stewardship.

Parent company Amneal Pharmaceuticals, Inc. has announced intentions to launch the topical anti-inflammatory agent in the third quarter of 2025.

An ongoing phase 1 study aims to prove the safety and tolerability of VAS-101, as well as its effect on blood flow dynamics, red blood cell sickling, and oxygen dissociation.

These data suggest that smoking history did not impact rates of malignancy, MACE, and VTE among those with atopic dermatitis treated with upadacitinib.

Preston describes lasting unmet needs in pulmonary arterial hypertension and reviews new pooled data supporting sotatercept’s long-term safety and efficacy.

Novartis has announced the safety and efficacy of iptacopan, a twice-daily oral monotherapy for adult patients who switched from eculizumab or ravulizumab.

The label expansion makes glecaprevir/pibrentasvir the first and only oral 8-week pangenotypic treatment option approved for people with acute or chronic HCV.

In this Q&A interview at RAD 2025, Tiffany Mayo, MD, highlights the biggest takeaways from her talk on complex cases in atopic dermatitis and hair loss.

Potentially the first successful CETP inhibitor, obicetrapib has shown positive trial results in reducing the risk of cardiovascular disease when combined with statins.

At SLEEP 2025, Axsome Therapeutics presented phase 3 ENCORE and SYMPHONY data showing AXS-12 reduced cataplexy attacks and improved daytime functioning in narcolepsy.

In this special episode, cohosts preview the most anticipated data and explore clinical implications in diabetes and obesity.

At SLEEP 2025, Fung discussed how combining a masked taper, CBT-I, and a nightly dose-tracking diary helped older adults achieve long-term benzodiazepine discontinuation.

At SLEEP 2025, Fung shared that masked taper plus CBT-I led to higher benzodiazepine discontinuation and improved sleep in older adults.

Mortality from ALD rose significantly across most demographic groups in the US from 1999 to 2022, especially during and following the COVID-19 pandemic onset.

In the second part of a 2-part episode, hosts Kimberly Brown and Nancy Reau break down 3 more notable abstracts from the 2025 EASL Congress.

In this RAD 2025 interview, Paller highlights her team’s findings on disease and family burden of topic dermatitis in children.

Gulati covers the promises and pitfalls of the healthcare world’s increasing focus on obesity as a disease and the variety of complications to which it gives rise.

In this interview, Yosipovitch touches on the topics featured in his RAD 2025 presentation ‘Managing Itch,’ specifically regarding patients with atopic dermatitis.

At SLEEP 2025, Danny Eckert, PhD, discussed new drug therapies for OSA, including tirzepatide, AD109, potassium channel blockers, and acetazolamide.